Melbourne, July 16, 2008 (ABN Newswire) - Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that the United States Patent and Trade Mark Office (USPTO) has granted a key patent, US Patent 7,399,632, through to at least the year 2019.
